Heparinized nanohydroxyapatite/collagen granules for controlled release of vancomycin by Coelho, Catarina C. et al.
Heparinized nanohydroxyapatite/collagen granules for controlled 
release of vancomycin
Catarina C. Coelho, Susana R. Sousa, Fernando J. Monteiro
Abstract: The purpose of this study was to develop a bone
substitute material capable of preventing or treating osteo-
myelitis through a sustainable release of vancomycin and
simultaneously inducing bone regeneration. Porous hepari-
nized nanohydroxyapatite (nanoHA)/collagen granules were
characterized using scanning electron microscopy, micro-
computed tomography and attenuated total reflectance Fou-
rier transform infrared spectroscopy. After vancomycin
adsorption onto the granules, its releasing profile was stud-
ied by UV molecular absorption spectroscopy. The hepari-
nized granules presented a more sustainable release over
time, in comparison with nonheparinized nanoHA and
nanoHA/collagen granules. Vancomycin was released for
360 h and proved to be bioactive until 216 h. Staphylococcus
aureus adhesion was higher on granules containing collagen,
guiding the bacteria to the material with antibiotic, improving
their eradication. Moreover, cytotoxicity of the released van-
comycin was assessed using osteoblast cultures, and after 14 
days of culture in the presence of vancomycin, cells were 
able to remain viable, increasing their metabolic activity and 
colonizing the granules, as observed by scanning electron 
microscopy and confocal laser scanning microscopy. These 
findings suggest that heparinized nanoHA/collagen granules 
are a promising material to improve the treatment of osteomy-
elitis, as they are capable of releasing vancomycin, eliminating 
the bacteria, and presented morphological and chemical char-
acteristics to induce bone regeneration. 
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INTRODUCTION
Osteomyelitis is an infection of bone caused by microorgan-
isms, and the evolution of the infection may cause bone
necrosis.1 Staphylococcus aureus is the most frequently
involved pathogen in this infection.1,2 Despite the improve-
ments in the treatment of osteomyelitis, it is still very difficult
for orthopedic surgeons to control this infection, particularly
when it is caused by resistant strains of S. aureus.3 The pros-
thetic devices are very susceptible to infections that are
caused mainly by S. aureus or coagulase-negative staphylo-
cocci (e.g., S. epidermidis).4 In a significant number of cases,
the prosthesis must be removed and replaced by another,
which implies a significant impact in terms of morbidity, mor-
tality, patient discomfort, and medical costs.5 The recom-
mended treatment for osteomyelitis caused by S. aureus is the
long-term parenteral administration of penicillin or vancomy-
cin. In addition, the parenteral administration for this treat-
ment involves the use of catheters, which have their own
infection-associated risks and problems.1 Vancomycin is a gly-
copeptide antibiotic with a molecular weight of approxi-
mately 1450 Da,6 and it is very effective against Gram-
positive bacteria, namely S. aureus.7 In fact, this antibiotic is
also capable of eradicating methicillin-resistant S. aureus
types in opposition to penicillin. Moreover, vancomycin
revealed low cytotoxicity for human osteoblasts, which is
essential for bone applications.8
Nanohydroxyapatite (nanoHA) is a calcium phosphate
material that is similar to natural apatite present in bone
well as its bioactivity against S. aureus. Moreover, S. aureus
adhesion to the produced granules was monitored, along
with the viability of MC3T3-E1 osteoblasts cultured on gran-
ules and in the presence of vancomycin.
MATERIALS AND METHODS
Production of nanoHA granules
NanoHA granules were obtained by crushing sintered scaf-
folds and at the end passing them in sieves with pore size
between 1.18 and 1.70 mm, obtaining granules with a gran-
ulometry between those two values. Scaffolds were pre-
pared using polyurethane sponge impregnation method
described elsewhere.9 Briefly, polyurethane sponges (Recti-
cel, Belgium) were impregnated with nanoHA slurry.9 The
slurry was prepared using a ratio of 5:4.4:0.2, respectively,
of nanoHA powder (g), ultrapure water (mL), and dispersive
agent Dolapix CE64 (mL) (Zschimmer & Schwarz, Germany).
The nanoHA is a highly pure spray-dried powder with an
average particle size of 5.06 1.0 mm, nanoXIMHAp202 (Flu-
idinova SA, Portugal), being composed by highly crystalline
nanoparticles aggregates, as confirmed by high-resolution
transmission electron microscopy (Fig. 1). The impregnated
sponges were dried at 37 C in the oven for approximately
30 min and then heat-treated in a sintering furnace (Ther-
molab). The heat treatment cycle used was as follows: heat-
ing rate of 1 C/min till 600 C with 1 h plateau, followed
by a heating rate of 4 C/min till 830 C with 1 h plateau.19
Afterward, the samples were naturally cooled inside the
furnace.
Collagen inclusion, crosslinking within nanoHA granules,
and heparin immobilization. A 0.5% (w/v) collagen solu-
tion was prepared by dissolving type I collagen (bovine
Achilles tendon, Sigma-Aldrich, St. Louis, MO) overnight in
HCl (0.01 M, pH5 2) at 4 C. The solution was then homog-
enized for 3 h using an Ultra Turrax (T25 D, IKAVR ) at
FIGURE 1. High-resolution transmission electron microscopy images of the nanoHA spray-dried powder. A: Nanosized HA aggregates. B: Nano-
crystalline structure, evidencing the Ca atoms in a perfect crystalline lattice. Image courtesy of Prof. Paulo J. Ferreira, Material Science and Engi-
neering Program, University of Texas at Austin and Fluidinova SA.
matrix as nanocrystals. When compared with micro-sized 
HA, nanoHA shows improved performance, because of large 
surface-to-volume ratio and higher surface reactivity.9 In 
fact, nanoHA has properties that can control protein adsorp-
tion such as grain size, pore size, and wettability.10 More-
over, nanoHA also enhances osteoblast functions like cell 
proliferation, calcium-containing mineral deposition, and 
alkaline phosphatase synthesis. NanoHA has already been 
studied as a potential material for drug-delivery systems, 
namely with vancomycin.3,11 Among the numerous forms of 
HA available for clinical applications, porous granules are 
more advantageous in cases of bone defects or hollows of 
irregular shapes,9 as it happens in patients with 
osteomyelitis.1
Type I collagen is a natural polymer present in bone12 
that has been increasingly used in tissue engineering and 
repair.12–14 This polymer has already been tested for the 
improvement of mechanical and biological properties of HA. 
The combination of the two materials described above is 
probably the most direct approach to obtain a bioactive arti-
ficial material that resembles natural bone, in terms of com-
position, nanostructure, and biological response.15
Heparin is a glycosaminoglycan present in the extracel-
lular matrix of different tissues16 and known to interact 
with several relevant biomolecules, such as growth factors 
and collagen.17,18 Therefore, immobilizing heparin on bioma-
terials may improve the performance of a drug-delivery sys-
tem, creating sustainable releasing conditions. This 
glycosaminoglycan was already immobilized in a HA/colla-
gen scaffold and proved to be a successful delivery system 
for bone morphogenic protein-2.18
This study aims at immobilizing heparin on nanoHA/col-
lagen granules to allow a controlled release of antibiotic to 
bone, filling a debrided and previously infected bone site. 
For that purpose, vancomycin was adsorbed onto nanoHA/
collagen granules, and its release profile was assessed, as
10,000 rpm on ice and then diluted to a 0.05% solution.
The nanoHA granules were spread on petri dishes, and a
single drop of collagen solution was applied in each granule.
Finally, the nanoHA granules were placed in a vacuum oven
(Binder, Germany) at room temperature (RT, 25 C) for 48 h
to allow collagen to penetrate the granules.
Collagen chemical crosslinking was performed using N-
(3-dimethylaminopropyl)-N0-ethylcarbodiimide (Aldrich, St.
Louis, MO) and N-hydroxysuccinimide (Fluka) described
elsewhere.18 Briefly, 27.6 mg of N-(3-dimethylaminopropyl)-
N0-ethylcarbodiimide and 10 mg of N-hydroxysuccinimide
were dissolved on 12 mL of 2-mofpholinoethane sulfonic
acid buffer (0.05 M, pH55.4, Sigma, St. Louis, MO). The
reaction was carried out for 2 h at 4 C. After the crosslink-
ing reaction, the solution was removed, and the samples
were washed three times with 2-mofpholinoethane sulfonic
acid buffer and dried overnight in a vacuum oven. Consider-
ing heparinized nanoHA/collagen granules, the collagen
crosslinking and heparin immobilization were performed as
described earlier, with the addition of heparin, along with
immobilization stoppage using phosphate-buffered saline
(PBS) and a washing procedure with NaCl and ultrapure
water.
Granules characterization
Scanning electron microscopy. Granules morphology, colla-
gen distribution, and chemical characterization were studied
using scanning electron microscopy (SEM) and energy-
dispersive X-ray spectroscopy (FEI Quanta 400 FEG SEM/
EDAX genesis X4M) with an acceleration voltage of 15 kV.
Previously, the samples were fixed with Araldite on the alu-
minum sample holder and sputter coated with an Au/Pd
alloy thin film for 90–110 s (SPI Module Sputter Coater) to
yield them electrical conductivity.
X-ray micro-computed tomography. Three-dimensional
(3D) structure of nanoHA and nanoHA/collagen granules
were assessed with X-ray micro-computed tomography
(micro-CT) Skyscan 1072 scanner (SkyScan, Kontich, Bel-
gium) in high-resolution mode of 6.69 mm x/y/z. Granules
were scanned for approximately 1 h each using a pixel size
of 3.29 mm. The energy and current of the X-ray source was
57 kV and 175 mA, respectively. A total of 250 slice images
(two-dimensional) were considered and converted into
binary images using a lower gray threshold of 60 and an
upper gray threshold of 255, in order to distinguish ceramic
material from pore voids. The slice images were assembled
to yield 3D images and reveal quantitative morphological
parameters. For two-dimensional and 3D image processing
and visualization, two SkyScan softwares were used: CT
Analyzer v.1.12.0.0 to obtain the morphological data and
CTVox to create the 3D models of the granules.
Attenuated total reflectance Fourier transform infrared
spectroscopy. The chemical composition of nanoHA,
nanoHA/collagen, and heparinized nanoHA/collagen gran-
ules and crosslinked collagen was assessed with attenuated
total reflectance Fourier transform infrared spectroscopy
(ATR-FTIR). For that purpose, an FTIR spectrometer (Perkin
Elmer 2000, Perkin Elmer, Waltham, MA) was used, with a
resolution of 4 cm21 and a frequency region from 400 to
4000 cm21, and 100 scans were accumulated per sample.
To perform ATR-FTIR, a Split Pea accessory (Harrick Scien-
tific, Pleasantville, NY) was used containing a silicon hemi-
spherical crystal.
Vancomycin release kinetics from granules
Vancomycin loading was performed by immersing 20 mg of
granules in Eppendorf tubes and in 1 mL of vancomycin
solution (Vancomicina Combino Pharm) with a concentra-
tion of 25 mg/mL (pH5 4). The antibiotic adsorption onto
granules was performed at 37 C and 120 rpm in the
orbital shaker (KS 4000 IC, IKAVR ) for 24 h.
After loading, the supernatant solution was removed,
and the granules were transferred to new Eppendorf tubes,
and 1 mL of PBS (pH57.4) was added. Eppendorf tubes
were placed in the orbital shaker at 37 C and 120 rpm. To
determine the vancomycin release from the granules, 200
mL of solution was withdrawn and replaced by fresh PBS
solution after 0.25, 0.5, 1.5, 2.5, 3.5, and 24 h and from then
onward every 24 h up to 360 h. Control experiments using
antibiotic-free ceramic samples was performed under the
same experimental conditions (negative control). The
removed solution was centrifuged for 5 min and
14,000 rpm to avoid particles in suspension. Vancomycin
concentration was determined by molecular absorption
spectroscopy at 280 nm using a spectrophotometer
(Lambda 35 UV/Vis Spectrometer, Perkin Elmer). The col-
lected samples were subsequently frozen at 220 C to per-
form microbiology assays. All tests were performed in
triplicate.
Vancomycin bioactivity
Vancomycin bioactivity was assessed using broth microdilu-
tion method.20 Therefore, S. aureus ATCC 25923 was grown
on nutrient broth (Liofilchem, Italy) for 24 h at 37 C and
120 rpm. From that bacterial suspension, an inoculum was
taken and adjusted to an absorbance (640 nm) of 0.2, corre-
sponding to 3.8 3 108 colony forming units (CFU)/mL.
Afterward, 96-well plates were filled with bacterial suspen-
sion (180 mL) and with the released vancomycin (20 mL).
For each time point, eight wells were used. Nutrient broth
without bacteria and bacterial suspension without vancomy-
cin were estabilished as controls. The plates were incubated
for 24 h at 37 C and 120 rpm. After incubation, the
absorbance was measured at 640 nm using a microplate
reader (Spectramax M2e, Molecular Devices, Sunnyvale, CA).
The absorbance values were converted to total number of
bacteria/mL using a calibration curve.
S. aureus adhesion to granules
Quantification of adherent S. aureus. The adherence of S.
aureus on three type of granules was studied to see
whether the bacterium has some tendency to migrate to
one type of granules rather than to another. With that objec-
tive, a nutrient agar (Liofilchem, Italy) plate inoculated with
samples were washed twice with PBS and then dehydrated
in graded series of ethanol. Hexamethyldisilazane (Sigma)
was added, and the samples were dried overnight at RT.
Granules were visualized on SEM as previously described.
Confocal laser scanning microscopy. Granules with
seeded cells were fixed using 4% paraformaldehyde for 15
min and then washed twice with PBS. Triton X-100 0.1%
was used, for 5 min, to permeabilize the cells, and the cells
were then incubated in 1% bovine serum albumin at 37 C
for 30 min. After incubation, the staining of the F-actin fila-
ments was performed using Alexa Fluor 594 Phalloidin
(1:100, Molecular Probes A12379, Invitrogen) in 1% bovine
serum albumin at RT for 20 min in dark. The samples were
then washed twice with PBS. Cell nuclei were stained with a
solution of Hoechst dye (1:1000, Sigma) in PBS at RT for 15
min in dark. Finally, the samples were washed twice with
PBS, and one drop of Vectashield was added. The images
were acquired with a Leica SP5 Confocal microscope, using
a 320 oil immersion objective. The obtained images were
processed with Leica Application Suite version 2.6.0.
Statistical analysis
The statistical analysis was performed using one-way analy-
sis of variance followed by a post hoc Tukey’s test with a
significance level of p< 0.05. The data analysis was done
using GraphPad Software version 5.02 (GraphPad software,
San Diego, CA).
RESULTS
Granules characterization
Granules morphology and collagen distribution were charac-
terized by SEM analysis. The obtained images revealed the
presence of interconnective macroporosity [Fig. 2(A)]. More-
over, SEM shows that collagen is distributed heterogene-
ously on nanoHA granules. For example, it can form large
collagen fibers across a macropore [Fig. 2(B,C)] or smaller
fibers covering the nanoHA grains [Fig. 2(D,E)]. The pres-
ence of microporosity [Fig. 2(E)] and nanoporosity [Fig.
2(F)] was also evident.
Micro-CT was performed to visualize the 3D structure of
the granules and to determine porosity (62.76 1.5%), mean
pore size (227.36 7.2 mm), and surface area
(26.66 5.6 mm2). The images obtained for the 3D structure
of a nanoHA granule show its irregular morphology and
interconnective macroporosity (Fig. 3).
The granules chemical composition was assessed using
ATR-FTIR (Fig. 4). The spectra revealed phosphate groups
at 473, 565, 600, 962, 1028, and 1088 cm21. The bands at
630 and 3572 cm21 correspond to OH2 vibrational and
stretching modes, respectively. Considering the samples con-
taining collagen, the characteristic peaks for amide I (C@O
stretching at 1600–1700 cm21), amide II (NAH deformation
at 1500–1550 cm21), and amide III (NAH deformation at
1200–1300 cm21) were obtained. The crosslinked collagen
sample has a broad band at 3200–3600 cm21, indicating
the presence of adsorbed water on the material.9 For the
heparinized nanoHA/collagen granules, there was no novel
S. aureus ATCC 25923 was used to create a 1.5 3 108 CFU/
mL suspension in 0.9% NaCl, which equals to 0.5 Mcfarland 
equivalence turbidity standard in ambient light, using a den-
sitometer (BioMerieux, France). To allow bacterial adhesion 
to granules, 20 mg of granules were placed in a glass tube 
with 1 mL of bacterial suspension and incubated in a gently 
shaking water bath at 37 C for 1 h. The experiment was 
performed in triplicate. After incubation, each sample was 
washed twice with 0.9% NaCl to remove loosely adhered or 
nonadherent bacteria. Then, 5 mL of 0.9% NaCl was added 
to each tube and sonicated for 1 s at 20 kHz using a sonica-
tor (Sonoplus HD 2200, Bandelin, Germany) with a MS 73 
probe. The sonicated solutions were used to obtain serial 
dilutions, and these were placed onto nutrient agar culture 
plates and incubated at 37 C for 18 h. Afterward, the num-
ber of adherent bacteria was counted, and the number of 
CFU/mm2 was determined.
Adherent S. aureus imaging. S. aureus was fixed using 
1.5% glutaraldehyde in cacodylate buffer (0.14 M) for 10 
min and dehydrated in graded series of ethanol solutions. 
The samples were dried overnight at RT. Adherent S. aureus 
on granules were visualized using SEM as previously 
described.
Osteoblast culture
MC3T3-E1 cells, an osteoblastic cell line derived from 
mouse calvaria, were grown in alpha minimum essential 
medium (Gibco, Life Technologies, Grand Island, NY), sup-
plemented with 1% penicillin–streptomycin (Gibco) and 
10% fetal bovine serum (Invitrogen, Carlsbad, CA). Cells 
were incubated in a humidified environment at 37 C and 
5% of CO2. Vancomycin adsorption on granules was per-
formed as mentioned earlier. Granules were placed in 96-
well plates, and cells were seeded using a density of 5 3 
104 cells/mL. Cells were cultured for 21 days, and medium 
was changed three times a week. As control, cells were cul-
tured on tissue culture polystyrene (TCPS) with the same 
conditions used for the granules. For each condition, six rep-
licates were used for the resazurin assay.
Metabolic activity. The nontoxic alamar blue (resazurin) 
dye was used to determine the metabolic activity of MC3T3-
E1 cells. The blue nonfluorescent dye is metabolized by 
cells, converting it to a reduced pink fluorescence dye.21 
Therefore, 10% (v/v) of resazurin was added to the 
medium and incubated for 4 h at 37 C and 5% of CO2. 
Afterward, 100 mL was transferred into a black 96-well 
plate, and fluorescence was measured at 530 nm excitation 
and 590 nm emission wavelength with a fluorescence 
reader (SynergyMix, BioTek, Winooski, VT) using Gen5 1.09 
Data Analysis Software. These measurements were made at 
24 h and 4, 7, 14, and 21 days of culture.
Cell morphology. Scanning electron microscopy. Gran-
ules with seeded cells were rinsed with PBS and fixer using 
1.5% gluteraldehyde (v/v) (Agar) in 0.14 M sodium cacodyl-
ate buffer (Merck, Kenilworth, NJ) at RT for 30 min. The
peaks present, as heparin peaks are superimposed over col-
lagen ones.22
Vancomycin release kinetics from granules
The vancomycin release from granules of nanoHA, nanoHA/
collagen, and heparinized nanoHA/collagen is shown in Fig-
ure 5. For the three types of granules, an initial burst of
antibiotic was observed in the first 15 min. The amount of
vancomycin released in the first 24 h was equal for the
three types of granules. However, after 24 h, the amount of
released antibiotic decreased for the nanoHA and nanoHA/
collagen granules. In opposition, the heparinized granules
continued a more sustainable release, with higher amounts
of vancomycin present, when compared with nonhepari-
nized granules. After 12 days, there was no antibiotic
detected for nanoHA and nanoHA collagen granules. For the
heparinized granules, the vancomycin release stopped after
15 days. Considering the released concentrations detected,
they were always higher than vancomycin minimum inhibi-
tory concentration (MIC) for S. aureus ATCC 25923 (1 mg/
mL) and below vancomycin minimum toxic concentration
(50 mg/mL) for the three types of granules.
Vancomycin bioactivity
As heparinized granules presented the best release profile,
the antibiotic bioactivity was assessed. The results show
that the released antibiotic was able to inhibit S. aureus
growth for 216 h (9 days) (Fig. 6). After that time point,
bacterial growth was observed in some replicates [Fig.
6(B)], and after 288 h, bacteria grew in all replicates. Figure
FIGURE 2. SEM images from nanoHA/collagen granules. A: Presence of interconnective macroporosity. B–D: Collagen distribution in a fiber-like
structure on nanoHA. E: Presence of microporosity. (F) Presence of nanoporosity.
FIGURE 3. 3D micro-CT images from a nanoHA/collagen granule from different perspectives, showing interconnective macroporosity throughout
all the granules structure. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
6 indicates the concentration values of antibiotic applied in
bacterial suspension. After 216 h, the concentrations were
lower than the MIC, and it was expected that bacteria will
grow. If not diluted, the release concentrations would be
able to inhibit bacterial growth, because they were always
higher than the MIC for S. aureus ATCC 25923.
S. aureus adhesion on granules
Figure 7 shows the results obtained for the bacterial adhe-
sion studies. It was observed that granules containing colla-
gen have higher number of adherent S. aureus, when
compared with nanoHA granules [Fig. 7(A)]. SEM images of
adherent bacteria on granules surface show that bacteria
adhered alone or in pairs. Moreover, bacteria were fre-
quently seen near the collagen fibers and between the
nanoHA grains [Fig. 7(B)].
MC3T3-e1 metabolic activity
In Figure 8, it is shown that there is no difference in the
metabolic activity after 24 h of culture for cells with and
without vancomycin. In the absence of this antibiotic, the
metabolic activity of the cells increased continuously until
the end of the culture. Considering the cells in the presence
of vancomycin, a decrease in metabolic activity was
observed until 7 days of culture. However, after 14 days of
culture, it was observed that cells in the presence of vanco-
mycin increased their metabolic activity and continued to
increase it until the end of the culture (21 days).
MC3T3-e1 morphology
SEM images (Fig. 9) show that after 24 h, cells without
vancomycin are elongated and spread on the granules sur-
face. In opposition, the cells in the presence of antibiotic
did not acquire an elongated shape after 24 h. Though,
after 7 days, all cells were elongated and well spread on
the granules surface, as it happened with cells without
antibiotic. After 14 days, an increase in cell number was
FIGURE 4. A: ATR-FTIR spectra of crosslinked collagen, nanoHA,
nanoHA/collagen, and heparinized nanoHA/collagen granules. B: Mag-
nification between 1150 and 1800 cm21 for crosslinked collagen,
nanoHA, nanoHA/collagen, and heparinized nanoHA/collagen gran-
ules, indicating the respective relevant peaks.
FIGURE 5. Vancomycin release from nanoHA, nanoHA/collagen, and heparinized nanoHA/collagen granules versus time. The values correspond
to the concentration present at each time point. *Represents a statistically significant difference compared with nanoHA and nanoHA/collagen
for each time point (p< 0.05).
observed for both cells with and without antibiotic, indicat-
ing that cells were proliferating. The results obtained with
confocal microscopy are consistent with those from SEM.
For the first time points (24 h and 4 days), it was observed
that cells adhered on both granules, but the cells in the
presence of vancomycin had a more rounded morphology
(Fig. 9). After 7 days, it could be seen that cells in the
presence of antibiotic started to elongate on the surface of
the material. After 14 days of culture, both cells with and
without vancomycin are well spread, covering the entire
surface.
DISCUSSION
This work proposed a novel material to be applied for the
treatment of osteomyelitis. This material was prepared to
allow a controlled release of vancomycin and further induce
bone regeneration. The heparinized nanoHA/collagen gran-
ules were prepared and subsequent chemical and morpho-
logical characterization was carried out. The vancomycin
release profile was evaluated as well as its bioactivity, S.
aureus adhesion, and effect of released vancomycin on via-
bility and morphology of MC3T3-E1 cells.
The produced granules presented adequate dimensions
(1.18–1.70 mm) to be used in cases of chronic osteomyelitis
because the defects present in this phase of infection nor-
mally are on the centimeters range in humans.23,24 More-
over, the size of the granules is also adequate to perform in
vivo studies using an osteomyelitis rat model.25
SEM images revealed the presence of interconnective
macroporosity, which is desirable for bone tissue regenera-
tion, as interconnectivity allows cell migration, neovasculari-
zation, and transport of nutrients and proteins. In addition,
the presence of macroporosity induces osteoinduction.26,27
Furthermore, the presence of micro [Fig. 2(E)] and nano-
porosity [Fig. 2(F)] on nanoHA was evident. Microporosity
is known to result in higher surface area that induces pro-
tein adsorption, ion exchange, and bone-like apatite forma-
tion.28 The presence of nanoporosity also improves protein
adsorption and enhances initial cell attachment29 because of
the large surface-to-volume ratio.9
Using micro-CT, it was only possible to assess micro-
porosity, as the equipment does not have enough resolution
to determine nanoporosity. Because the collagen fibers are
transparent to X-rays, it was also impossible to detect colla-
gen on granules. The average macroporosity of the granules
is 62.761.5%, being adequate for bone regeneration.28 The
value of surface area (26.665.6 mm2) is considered high,
taking into account the granules size distribution (1.18–
1.70 mm). If these particles were spherical and without
pores, the geometric area would be between 4.27 and
9.07 mm2, which is much lower than the obtained area. The
average mean pore size obtained was 227.367.2 lm, which
is adequate for osteogenesis. The minimum requirement for
pore size is approximately 100 lm because of cell size and
cell migration.28 Moreover, previous studies from our group
revealed that nanoHA granules in a co-culture system with
FIGURE 6. A: Total number of S. aureus in the absence of vancomycin, for 0 and 24 h of incubation, and in the presence of vancomycin after
24 h of incubation. *Represents a statistically significant difference compared with S. aureus 0 h and S. aureus 24 h (p< 0.05). B: S. aureus
growth inhibition for each time point of released vancomycin. (2) No growth; (1) Growth in one replicate; (11) Growth in two replicates;
(111) Growth in five replicates.
FIGURE 7. A: S. aureus adhesion onto nanoHA, nanoHA/collagen, and heparinized nanoHA/collagen granules expressed as CFU per mm2 of
granules. *Represents a statistically significant difference compared with nanoHA granules (p<0.05); B: SEM images of adherent S. aureus on
granules (1, nanoHA; 2, nanoHA/collagen; and 3, heparinized nanoHA/collagen).
FIGURE 8. Metabolic activity of MC3T3-E1 cells cultured with heparinized nanoHA/collagen granules with and without vancomycin. Results are
expressed in terms of relative fluorescence units (RFU) per mm2 of granules. TCPS was used as a control. *Represents a statistically significant
difference compared with heparinized nanoHA/collagen granules without vancomycin for the same time point (p< 0.05). **Represents a statisti-
cally significant difference compared with heparinized nanoHA/collagen granules with vancomycin at 24 h and 4, 7, and 14 days (p< 0.05).
***Represents a statistically significant difference compared with heparinized nanoHA/collagen granules without vancomycin at 24 h and 4 and
7 days (p< 0.05).
human mesenchymal stem cells and human dermal micro-
vascular endothelial cells (HDMECs) showed positive effects
in both angiogenic and osteogenic behaviors. Particularly,
nanoHA granules provided appropriate environment for
both human mesenchymal stem cells and HDMECs to
adhere, migrate, and proliferate, maintaining their character-
istic gene expression markers. Moreover, HDMECs in the
presence of nanoHA granules were capable to form
capillary-like tubes just after 3 days of culture.30
Considering the vancomycin release from granules, it
was seen that heparinized nanoHA/collagen granules are
able to release higher amounts of antibiotic in a more sus-
tainable way, compared with nanoHA and nanoHA/collagen
granules. The released vancomycin concentrations were
always above S. aureus MIC and below minimum toxic con-
centration.31 Therefore, the released antibiotic is enough to
inhibit S. aureus growth without becoming toxic. Moreover,
an initial burst of release was observed, followed by a sus-
tained release. This release profile is recommended to have
a complete eradication of the pathogen.5 The interaction
between HA and vancomycin can be explained because HA
is mostly negatively charged,32 and so cationic vancomycin
can adsorb onto HA. Collagen is positively charged during
vancomycin adsorption (acidic pH),33 being unlikely that
these two molecules interact strongly as they both have the
same charge.34 Therefore, the similar releasing profile
between these two types of granule surfaces probably is
dependent on HA and the presence of nanoporosity, as van-
comycin molecules can be more entrapped on the structure
and consequently released slowlier.35 The difference
observed for heparinized nanoHA/collagen granules may be
because heparin contains negatively charged groups (car-
boxylic and sulfur) and shows a tendency for protein bind-
ing.36 Consequently, vancomycin has two characteristics that
promote its interaction with heparin, increasing its adsorp-
tion: it is a cation and a glycopeptide. The release of vanco-
mycin from granules can be explained by a change in the
net charge of this antibiotic: as granules were placed in a
solution at physiological pH (PBS solution), vancomycin net
charge decreased, becoming less positive.37,38 Therefore, the
FIGURE 9. SEM and CLSM images of MC3T3-E1 cells morphology on heparinized nanoHA/collagen granules with and without vancomycin after
1, 4, 7, 14, and 21 days of culture. F-actin is represented in red, whereas cell nuclei were counterstained in blue with Hoechst stain. MC3 T3-E1
on TCPS was used as a control (data not shown). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
cells were able to recover and proliferate, as it was
observed in CLSM and SEM images (Fig. 9). In fact, osteo-
blasts in the presence of vancomycin started to increase
their metabolic activity and proliferate at day 14, which cor-
responds to the period when vancomycin release ended.
Therefore, after vancomycin release, the osteoblasts that
remained viable begun to recover from the presence of anti-
biotic. The obtained results for this assay are promising
because osteoblasts were able to adhere and proliferate
even in the presence of vancomycin.
CONCLUSIONS
In this work, it was possible to produce an innovative con-
trolled releasing system aimed at improving the treatment
of osteomyelitis through local antibiotic release. Porous hep-
arinized nanoHA/collagen granules were successfully pro-
duced and exhibited interconnective macro-, micro-, and
nanoporosity. This material also allowed a more sustainable
and controlled release of vancomycin for 360 h (15 days),
when compared with nonheparinized granules. The antibi-
otic released from heparinized granules was bioactive and
capable of inhibiting S. aureus growth. The bacterial adhe-
sion studies revealed that S. aureus adhere in higher num-
ber on granules containing collagen, and this behavior may
improve their eradication. The presence of vancomycin did
not affect the viability of MC3T3-E1 cells, as they were able
to remain viable in the presence of the antibiotic and prolif-
erate after 14 days of culture. We can envisage that the
material herein developed can first eradicate osteomyelitis
and then promote the renewal of bone.
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